4-benzyloxy-5-methoxy-2-nitrobenzamide | 60547-94-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyloxy-5-methoxy-2-nitrobenzamide
• 英文别名: 5-Methoxy-2-nitro-4-(phenylmethoxy)benzamide；4-(Benzyloxy)-5-methoxy-2-nitrobenzamide；5-methoxy-2-nitro-4-phenylmethoxybenzamide
• CAS: 60547-94-6
• 化学式: C₁₅H₁₄N₂O₅
• 分子量: 302.287
• InChiKey: UCDVVZZVBFQPJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-benzyloxy-5-methoxy-2-nitrobenzamide 在 铁粉 、 溶剂黄146 作用下， 反应 2.5h， 以38%的产率得到2-氨基-4-苄氧基-5-甲氧基苯甲酰胺
  参考文献：
  名称：

  Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping

  摘要：

  An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.08.017
• 作为产物：
  描述：

  2-硝基-4-苄氧基-5-甲氧基苯甲酸 在 草酰氯 、 氨 作用下， 以 甲苯 、 1,4-二氧六环 为溶剂， 反应 4.0h， 以99%的产率得到4-benzyloxy-5-methoxy-2-nitrobenzamide
  参考文献：
  名称：

  [EN] QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS
  [FR] DÉRIVÉS DE QUINOLINE OU DE QUINAZOLINE AYANT UNE ACTIVITÉ INDUISANT L'APOPTOSE SUR LES CELLULES

  摘要：

  公开号：

  WO2012030160A3

文献信息

• Oxindolylquinazoline derivatives as angiogenesis inhibitors
  申请人：Zeneca Limited

  公开号：US06294532B1

  公开（公告）日：2001-09-25

  The invention relates to compounds of formula (I) and salts thereof as further defined herein, wherein ring Z is a 6-membered heterocyclic ring containing 1 to 3 nitrogen atoms, and the use of such compounds and salts to inhibit the effects of VEGF and FGF, and in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  该发明涉及公式（I）的化合物及其盐，如本文所进一步定义的，其中环Z是含有1至3个氮原子的6元杂环环，以及利用这些化合物和盐来抑制VEGF和FGF的作用，并用于治疗包括癌症和类风湿性关节炎在内的多种疾病状态。
• QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS
  申请人：Bae In Hwan

  公开号：US20130165386A1

  公开（公告）日：2013-06-27

  Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

  提供的是一种药物组合物，包含一种式子为(I)的喹啉或喹嗪衍生物作为活性成分，以及其药学上可接受的盐、异构体、水合物和溶剂化物。该组合物对于预防和治疗由凋亡抑制蛋白(IAPs)过度表达引起的癌症、炎症、自身免疫性疾病或神经退行性疾病具有有效性。
• OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
  申请人：ZENECA LIMITED

  公开号：EP1005470A1

  公开（公告）日：2000-06-07
• US4950674A
  申请人：——

  公开号：US4950674A

  公开（公告）日：1990-08-21
• US6294532B1
  申请人：——

  公开号：US6294532B1

  公开（公告）日：2001-09-25